By Fineline Cube 
Enhertu (trastuzumab deruxtecan), the HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568), received National Medical Products Administration (NMPA) approval in China as sequential therapy following paclitaxel, trastuzumab, and pertuzumab (THP) for neoadjuvant treatment of adult patients with HER2-positive stage II (high-risk) or stage III breast cancer. The approval, based on Phase III DESTINY-Breast11 data, demonstrated a statistically significant 11.2 percentage-point improvement in pathological complete response (pCR) rate versus standard chemotherapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Marketing authorization (neoadjuvant indication) |
| Product | Enhertu (trastuzumab deruxtecan) – HER2-directed ADC |
| Developers | AstraZeneca + Daiichi Sankyo (co-development) |
| Indication | HER2+ stage II (high-risk) or stage III breast cancer – sequential therapy post-THP |
| Supporting Data | Phase III DESTINY-Breast11 trial |
DESTINY-Breast11 Phase III Results
| Endpoint | Enhertu + THP | ddAC-THP (Standard) | Improvement | Statistical Significance |
|---|---|---|---|---|
| Pathological Complete Response (pCR) | 67.29% | 56.25% | +11.2 percentage points | p=0.003 (95% CI: 4.0–18.3) |
| Event-Free Survival (EFS) | Trend favoring Enhertu | — | HR=0.56 | Early signal (4.5% maturity) |
Subgroup Consistency: pCR improvements observed across hormone receptor-positive and -negative disease; China subgroup analysis confirmed global trend
Strategic Context & Market Impact
| Factor | Implication |
|---|---|
| China HER2+ Early Breast Cancer | ~30,000–40,000 annual cases; neoadjuvant therapy standard of care; pCR correlates with long-term outcomes |
| Enhertu Franchise Expansion | Already approved in metastatic HER2+ BC, HER2-low BC, HER2+ gastric, HER2-mutant lung; early-stage BC adds $1+ billion potential |
| ADC Standard of Care Shift | First ADC in neoadjuvant setting – challenges traditional chemotherapy backbone (ddAC); potential for label expansion to adjuvant |
| Sequential Strategy | THP → Enhertu → surgery approach optimizes pCR while preserving cardiac safety vs. concurrent HER2-blockade concerns |
| Competitive Dynamics | Positions vs. Kadcyla (T-DM1) adjuvant and emerging HER2 bispecifics (Zymeworks, Alphamab) in early-stage space |
- Commercial Timeline: China launch Q2 2026; NRDL negotiation 2027 for reimbursement access; global regulatory filings (FDA, EMA) anticipated H2 2026
- Revenue Synergy: Enhertu global sales projected $8+ billion annually by 2028; China early-stage indication contributes $300–500 million peak
Forward‑Looking Statements
This brief contains forward‑looking statements regarding EFS maturity, long-term survival outcomes, and reimbursement negotiations for Enhertu in early-stage HER2+ breast cancer. Actual results may differ due to competitive dynamics with HER2-targeted therapies, cardiac safety surveillance, and pricing pressure in the China oncology market.-Fineline Info & Tech